Displaying drugs 14251 - 14275 of 15262 in total
Fordadistrogene movaparvovec
Investigational
Pariglasgene brecaparvovec
Investigational
Patidistrogene bexoparvovec
Investigational
Domofenogene zalfaparvovec
Domofenogene zalfaparvovec, formerly known as BMN-307, is an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy developed by BioMarin Pharmaceutical.
Experimental
Ifezuntirgene inilparvovec
Experimental
Ixoberogene soroparvovec
Investigational
Zaftuclenegene piruparvovec
Experimental
Human Laminin-111
Investigational
Recombinant methionyl brain-derived neurotrophic factor
Investigational
Tegoprubart
Investigational
ABO-202
Investigational
Spheramine
Investigational
BBP-812
Investigational
TSHA-120
Investigational
TVN-102
Investigational
Vesleteplirsen
Investigational
CV-MG01
Investigational
AT-GTX-502
AT-GTX-502 is an experimental, one-time gene therapy that uses AAV9 to deliver a functional copy of CLN3.
Investigational
BMN-045
Experimental
Withdrawn
AMZ002
AMZ002 is a sterile injectable hormone developed as a purified synthetic polypeptide alternative to current FDA-approved epileptic seizure treatments.
Investigational
IMCY-0141
IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin sheath protecting the nerves.
Investigational
Matched Description: … Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and …
AVI-014
AVI-014 is a glycosylated, recombinant human granulocyte colony-stimulating factor (G-CSF).
Investigational
Autologous Human Peripheral Blood Lymphocytes
Investigational
P140K methylguanine-DNA-methyltransferase mutant CD34+ cells
Investigational
Displaying drugs 14251 - 14275 of 15262 in total